Literature DB >> 22058149

Diabetes-induced vascular dysfunction involves arginase I.

Maritza J Romero1, Jennifer A Iddings, Daniel H Platt, M Irfan Ali, Stephen D Cederbaum, David W Stepp, Ruth B Caldwell, Robert W Caldwell.   

Abstract

Arginase can cause vascular dysfunction by competing with nitric oxide synthase for l-arginine and by increasing cell proliferation and collagen formation, which promote vascular fibrosis/stiffening. We have shown that increased arginase expression/activity contribute to vascular endothelial cell (EC) dysfunction. Here, we examined the roles of the two arginase isoforms, arginase I and II (AI and AII, respectively), in this process. Experiments were performed using streptozotocin-induced diabetic mice: wild-type (WT) mice and knockout mice lacking the AII isoform alone (AI(+/+)AII(-/-)) or in combination with partial deletion of AI (AI(+/-)AII (-/-)). EC-dependent vasorelaxation of aortic rings and arterial fibrosis and stiffness were assessed in relation to arginase activity and expression. Diabetes reduced mean EC-dependent vasorelaxation markedly in diabetic WT and AI(+/+)AII(-/-) aortas (53% and 44% vs. controls, respectively) compared with a 27% decrease in AI(+/-)AII (-/-) vessels. Coronary fibrosis was also increased in diabetic WT and AI(+/+)AII(-/-) mice (1.9- and 1.7-fold vs. controls, respectively) but was not altered in AI(+/-)AII (-/-) diabetic mice. Carotid stiffness was increased by 142% in WT diabetic mice compared with 51% in AI(+/+)AII(-/-) mice and 19% in AI(+/-)AII (-/-) mice. In diabetic WT and AI(+/+)AII(-/-) mice, aortic arginase activity and AI expression were significantly increased compared with control mice, but neither parameter was altered in AI(+/-)AII (-/-) mice. In summary, AI(+/-)AII (-/-) mice exhibit better EC-dependent vasodilation and less vascular stiffness and coronary fibrosis compared with diabetic WT and AI(+/+)AII(-/-) mice. These data indicate a major involvement of AI in diabetes-induced vascular dysfunction.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22058149      PMCID: PMC3334242          DOI: 10.1152/ajpheart.00774.2011

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  36 in total

1.  Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function.

Authors:  C Zhang; T W Hein; W Wang; C I Chang; L Kuo
Journal:  FASEB J       Date:  2001-05       Impact factor: 5.191

Review 2.  Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness: clinical applications.

Authors:  Athanase Benetos; Bernard Waeber; Joseph Izzo; Gary Mitchell; Lawrence Resnick; Roland Asmar; Michel Safar
Journal:  Am J Hypertens       Date:  2002-12       Impact factor: 2.689

3.  Increased expression of arginase II in human diabetic corpus cavernosum: in diabetic-associated erectile dysfunction.

Authors:  T J Bivalacqua; W J Hellstrom; P J Kadowitz; H C Champion
Journal:  Biochem Biophys Res Commun       Date:  2001-05-18       Impact factor: 3.575

4.  Generation of a mouse model for arginase II deficiency by targeted disruption of the arginase II gene.

Authors:  O Shi; S M Morris; H Zoghbi; C W Porter; W E O'Brien
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

5.  Endothelium-derived nitric oxide regulates arterial elasticity in human arteries in vivo.

Authors:  S Kinlay; M A Creager; M Fukumoto; H Hikita; J C Fang; A P Selwyn; P Ganz
Journal:  Hypertension       Date:  2001-11       Impact factor: 10.190

6.  Angiotensin II activates collagen type I gene in the renal vasculature of transgenic mice during inhibition of nitric oxide synthesis: evidence for an endothelin-mediated mechanism.

Authors:  J J Boffa; P L Tharaux; S Placier; R Ardaillou; J C Dussaule; C Chatziantoniou
Journal:  Circulation       Date:  1999-11-02       Impact factor: 29.690

7.  Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice.

Authors:  P J Kuhlencordt; R Gyurko; F Han; M Scherrer-Crosbie; T H Aretz; R Hajjar; M H Picard; P L Huang
Journal:  Circulation       Date:  2001-07-24       Impact factor: 29.690

8.  Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells.

Authors:  H Li; C J Meininger; J R Hawker; T E Haynes; D Kepka-Lenhart; S K Mistry; S M Morris; G Wu
Journal:  Am J Physiol Endocrinol Metab       Date:  2001-01       Impact factor: 4.310

Review 9.  Arginases I and II: do their functions overlap?

Authors:  Stephen D Cederbaum; Hong Yu; Wayne W Grody; Rita M Kern; Paul Yoo; Ramaswamy K Iyer
Journal:  Mol Genet Metab       Date:  2004-04       Impact factor: 4.797

10.  Protein disregulation in red blood cell membranes of type 2 diabetic patients.

Authors:  Ming Jiang; Linzhi Jia; Weihua Jiang; Xiaojian Hu; Hanqing Zhou; Xin Gao; Zhiqiang Lu; Zhihong Zhang
Journal:  Biochem Biophys Res Commun       Date:  2003-09-12       Impact factor: 3.575

View more
  44 in total

1.  Hyperglycemia-impaired aortic vasorelaxation mediated through arginase elevation: Role of stress kinase pathways.

Authors:  Surabhi Chandra; David J R Fulton; Ruth B Caldwell; R William Caldwell; Haroldo A Toque
Journal:  Eur J Pharmacol       Date:  2018-11-28       Impact factor: 4.432

Review 2.  Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis.

Authors:  Naoki Sawada; James K Liao
Journal:  Antioxid Redox Signal       Date:  2013-09-24       Impact factor: 8.401

Review 3.  Arginase: an old enzyme with new tricks.

Authors:  Ruth B Caldwell; Haroldo A Toque; S Priya Narayanan; R William Caldwell
Journal:  Trends Pharmacol Sci       Date:  2015-04-27       Impact factor: 14.819

4.  1,5-Anhydroglucitol predicts CKD progression in macroalbuminuric diabetic kidney disease: results from non-targeted metabolomics.

Authors:  Gesiane Tavares; Gabriela Venturini; Kallyandra Padilha; Roberto Zatz; Alexandre C Pereira; Ravi I Thadhani; Eugene P Rhee; Silvia M O Titan
Journal:  Metabolomics       Date:  2018-02-27       Impact factor: 4.290

5.  Tissue-specific up-regulation of arginase I and II induced by p38 MAPK mediates endothelial dysfunction in type 1 diabetes mellitus.

Authors:  J Pernow; A Kiss; Y Tratsiakovich; B Climent
Journal:  Br J Pharmacol       Date:  2015-08-10       Impact factor: 8.739

6.  The role of arginase I in diabetes-induced retinal vascular dysfunction in mouse and rat models of diabetes.

Authors:  S C Elms; H A Toque; M Rojas; Z Xu; R W Caldwell; R B Caldwell
Journal:  Diabetologia       Date:  2012-12-12       Impact factor: 10.122

7.  Vitamin D is a regulator of endothelial nitric oxide synthase and arterial stiffness in mice.

Authors:  Olena Andrukhova; Svetlana Slavic; Ute Zeitz; Sabine C Riesen; Monika S Heppelmann; Tamas D Ambrisko; Mato Markovic; Wolfgang M Kuebler; Reinhold G Erben
Journal:  Mol Endocrinol       Date:  2013-01-01

8.  Role for high-glucose-induced protein O-GlcNAcylation in stimulating cardiac fibroblast collagen synthesis.

Authors:  Hugo Aguilar; Eduardo Fricovsky; Sang Ihm; Magdalena Schimke; Lisandro Maya-Ramos; Nakon Aroonsakool; Guillermo Ceballos; Wolfgang Dillmann; Francisco Villarreal; Israel Ramirez-Sanchez
Journal:  Am J Physiol Cell Physiol       Date:  2014-02-19       Impact factor: 4.249

9.  Prevention of diabetes-induced arginase activation and vascular dysfunction by Rho kinase (ROCK) knockout.

Authors:  Lin Yao; Surabhi Chandra; Haroldo A Toque; Anil Bhatta; Modesto Rojas; Ruth B Caldwell; R William Caldwell
Journal:  Cardiovasc Res       Date:  2012-12-17       Impact factor: 10.787

10.  HuangqiGuizhiWuwu Decoction Prevents Vascular Dysfunction in Diabetes via Inhibition of Endothelial Arginase 1.

Authors:  Hong Cheng; Tian Lu; Jingya Wang; Yucen Xia; Xiaoshu Chai; Minyi Zhang; Yutong Yao; Na Zhou; Sisi Zhou; Xinyi Chen; Weiwei Su; Cunzhi Liu; Wei Yi; Yongjun Chen; Lin Yao
Journal:  Front Physiol       Date:  2020-03-25       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.